NASDAQ:GLMD

Galmed Pharmaceuticals - GLMD Stock Forecast, Price & News

$0.29

-0.01 (-3.31%)

(As of 11/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.29
▼
$0.31
50-Day Range: $0.30
▼
$0.47
52-Week Range: $0.29
▼
$2.73

Volume: 20,104 shs
Average Volume: 89,693 shs
Market Capitalization: $7.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Galmed Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 1,566.7% Upside
$5.00 Price Target
Short Interest: Healthy
0.08% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.19
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.73) to ($0.64) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

3.0

Analyst's Opinion

Consensus Rating
Galmed Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Galmed Pharmaceuticals has a forecasted upside of 1,566.7% from its current price of $0.30.
Amount of Analyst Coverage
Galmed Pharmaceuticals has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.08% of the float of Galmed Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Galmed Pharmaceuticals has recently decreased by 45.86%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Galmed Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Galmed Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GLMD.

2.3

News and Social Media Coverage

News Sentiment
Galmed Pharmaceuticals has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Galmed Pharmaceuticals this week, compared to 0 articles on an average week.
MarketBeat Follows
1 people have added Galmed Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 10.04% of the stock of Galmed Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Galmed Pharmaceuticals are expected to grow in the coming year, from ($0.73) to ($0.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Galmed Pharmaceuticals is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Galmed Pharmaceuticals is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Galmed Pharmaceuticals has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Galmed Pharmaceuticals (NASDAQ:GLMD) Stock

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Stock News Headlines

November 22, 2022 | americanbankingnews.com

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com

November 22, 2022 | americanbankingnews.com

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com

November 22, 2022 | americanbankingnews.com

FY2022 Earnings Estimate for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Issued By HC Wainwright

September 14, 2022 | finance.yahoo.com

Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade

August 4, 2022 | finance.yahoo.com

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

July 7, 2022 | finance.yahoo.com

Galmed's Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal Model

July 7, 2022 | nasdaq.com

Galmed: New Data Reinforces Expansion Of Aramchol's Clinical Development To Additional Indications

July 7, 2022 | finance.yahoo.com

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

June 17, 2022 | finance.yahoo.com

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

May 25, 2022 | benzinga.com

Galmed Pharmaceuticals (NASDAQ:GLMD), Analyst Ratings, Price Targets, Predictions

May 18, 2022 | seekingalpha.com

Galmed Pharmaceuticals shares fall after downgrade by Raymond James analyst

May 17, 2022 | finance.yahoo.com

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

May 17, 2022 | finance.yahoo.com

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

May 3, 2022 | marketwatch.com

Galmed Pharmaceuticals Shares Down 16%

May 3, 2022 | markets.businessinsider.com

Raymond James Maintains Outperform Rating for Galmed Pharmaceuticals: Here's What You Need To Know

May 2, 2022 | seekingalpha.com

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript

May 2, 2022 | finance.yahoo.com

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

April 29, 2022 | benzinga.com

Galmed Pharmaceuticals's Earnings Outlook

April 28, 2022 | finance.yahoo.com

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

April 26, 2022 | finance.yahoo.com

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

January 11, 2022 | seekingalpha.com

Galmed gains 5% after securing three new U.S. patents for Aramchol and meglumine salt

January 11, 2022 | nasdaq.com

Galmed Pharmaceuticals Ltd Shares Fall 5.2% Below Previous 52-Week Low - Market Mover

January 11, 2022 | finance.yahoo.com

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

January 10, 2022 | finance.yahoo.com

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

November 11, 2021 | nasdaq.com

Here's Why We're Watching Galmed Pharmaceuticals' (NASDAQ:GLMD) Cash Burn Situation

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Company Calendar

Last Earnings: 11/08/2021
Today: 11/30/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 5/01/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GLMD
CUSIP: N/A
CIK: 1595353
Web: www.galmedpharma.com
Phone: (723) 693-8448
Fax: 972-3693-8447
Employees: 18
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +1,612.9%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.90)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-32,470,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -97.97%
Return on Assets: -80.42%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 4.07
Quick Ratio: 4.07

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.63 per share
Price / Book: 0.46

Miscellaneous

Outstanding Shares: 25,088,000
Free Float: N/A
Market Cap: $7.32 million
Optionable: Optionable
Beta: 1.51

Key Executives

Mr. Allen Baharaff (Age 57)
Co-Founder, Pres, CEO & Chairman
Comp: $1.71M

Mr. Guy Nehemya (Age 37)
COO & Data Protection Officer
Comp: $168.93k

Mr. Yohai Stenzler CPA (Age 39)
Chief Accounting Officer
Comp: $173.11k

Dr. Liat Hayardeny (Age 55)
Chief Scientific Officer
Comp: $263.01k

Mr. Doron Cohen (Age 55)
Chief Financial Officer

Ms. Yael Hollander (Age 39)
VP of Legal Affairs & Strategy

Ms. Shani Ganon
HR Mang.

Dr. Tali Gorfine (Age 52)
Medical Consultant

Mr. Niv Alon
Head of PMO

Key Competitors

View All Competitors

GLMD Stock - Frequently Asked Questions

Should I buy or sell Galmed Pharmaceuticals stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GLMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLMD, but not buy additional shares or sell existing shares.
View GLMD analyst ratings or view top-rated stocks.
What is Galmed Pharmaceuticals' stock price forecast for 2023?: 5 Wall Street analysts have issued 12-month price objectives for Galmed Pharmaceuticals' stock. Their GLMD share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 1,612.9% from the stock's current price.
View analysts price targets for GLMD or view top-rated stocks among Wall Street analysts.
How have GLMD shares performed in 2022?: Galmed Pharmaceuticals' stock was trading at $1.82 at the beginning of 2022. Since then, GLMD stock has decreased by 84.0% and is now trading at $0.2919.
View the best growth stocks for 2022 here.
Are investors shorting Galmed Pharmaceuticals?: Galmed Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 18,300 shares, a decrease of 45.9% from the October 31st total of 33,800 shares. Based on an average daily volume of 41,100 shares, the short-interest ratio is currently 0.4 days. Approximately 0.1% of the shares of the stock are short sold.
View Galmed Pharmaceuticals' Short Interest.
When is Galmed Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023.
View our GLMD earnings forecast.

How were Galmed Pharmaceuticals' earnings last quarter?: Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.04.
What other stocks do shareholders of Galmed Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).
What is Galmed Pharmaceuticals' stock symbol?: Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."
How do I buy shares of Galmed Pharmaceuticals?: Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Galmed Pharmaceuticals' stock price today?: One share of GLMD stock can currently be purchased for approximately $0.29.
How much money does Galmed Pharmaceuticals make?: Galmed Pharmaceuticals (NASDAQ:GLMD) has a market capitalization of $7.32 million. The biopharmaceutical company earns $-32,470,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.
How can I contact Galmed Pharmaceuticals?: Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The official website for the company is www.galmedpharma.com. The biopharmaceutical company can be reached via phone at (723) 693-8448, via email at investor.relations@galmedpharma.com, or via fax at 972-3693-8447.

This page (NASDAQ:GLMD) was last updated on 11/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Galmed Pharmaceuticals - GLMD Stock Forecast, Price & News

Galmed Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Galmed Pharmaceuticals (NASDAQ:GLMD) Stock

GLMD Stock News Headlines

GLMD Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

GLMD Stock - Frequently Asked Questions

Overall MarketRank^™